Therapeutic Options Are About To Change for Breast Cancer As New Data Is Emerging, For the Recent Approved Aromatase Inhibitor.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41019) has announced the addition of Analytical analytical, analytic pertaining to or emanating from analysis. analytical control control of confounding by analysis of the results of a trial or test. Tool - Breast Cancer R&D Comprehensive Guide to their offering. This is the second analytical tool to analyze the future competitive situation of breast cancer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development. As new data is emerging, for the recent approved aromatase inhibitor aromatase inhibitor n. A drug that inhibits tumor growth, especially breast cancer, by inhibiting the enzyme aromatase and thereby lowering estrogen levels in the blood or in tumor tissues. , the therapeutic options are about to change. Replacing Tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. , a selective estrogen receptor modulator se·lec·tive estrogen receptor modulator n. Abbr. SERM A nonsteroidal compound, such as raloxifene or tamoxifen, designed to mimic the effect of estrogen on a specific tissue or body part by binding only to that part's estrogen receptors. that has been used for more than 20 years to treat patients with advanced breast cancer. Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval. A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales for the top three breast cancer hormone therapies Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy on the market reaching more than $1.8 billion. "Analytical Tool: Breast Cancer R&D: A Comprehensive Guide" is the ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Those who are victorious in the field plan effectively and change decisively. It provides a complete and systematic description and analysis of the past, present and future efforts in cancer R&D from both industry as well as academic. The guide has identified structured and defined information necessary to analyze the most candidates currently under development. The included CD-ROM CD-ROM: see compact disc. CD-ROM in full compact disc read-only memory Type of computer storage medium that is read optically (e.g., by a laser). database contains thousands of records on the issue of R&D and collaborations derived from a multitude of sources, e.g. news releases, company sources, conferences, scientific publications, patents and published interviews etc. This highly updated database reflects the most recent advances in the field. Enabling you and to offer you an opportunity to easily produce tables and graphs of the information suited for your own specific purposes. Reasons to read this Analytical Tool: --This is the only product that provides you with a complete structure of the areas involved in analyzing breast therapeutics. --It identifies and structures most B2B (Business to Business) Refers to one business communicating with or selling to another. See B2B e-commerce, B2C and B2G. B2B - business to business collaborations and industry-academic alliances --It covers close to all areas of cancer therapeutic strategies you will be able to study areas in conjunction to cancer structured by therapy type, drug effects, mechanisms/targets and combinatory therapies --It enables you to track cutting edge competitive companies, therapies and technologies in the future market --You will save time and money by rapid identification and analysis of competitors and business opportunities. --You will be able to evaluate progress in both established as well as novel treatment strategies competing within the field of cancer drug development in big pharma. Included products in this Analytical Tool --Breast Cancer: The Latest R&D Trends --Breast Cancer Drug Pipeline Update 2006 For more information visit http://www.researchandmarkets.com/reports/c41019 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion